Silence Therapeutics Plc Stock Price, News & Analysis

Silence Therapeutics plc (AIM: SLN, Nasdaq: SLN) announced that Frazier Life Sciences has acquired approximately $20 million worth of ordinary shares, becoming a 3% shareholder. This partnership underscores Silence’s potential in RNA interference technology and enhances its financial backing as it progresses with two clinical stage programs and expands its pre-clinical pipeline using its mRNAi GOLD™ platform. The move aligns with Silence's strategy to attract institutional investors, particularly after its delisting from AIM.

Silence Therapeutics (AIM:SLN, Nasdaq:SLN) announced updates on its mRNAi GOLD™ platform during its R&D Day on October 21, 2021. Key highlights include plans to initiate a Phase 1 study for polycythemia vera (PV) using SLN124, targeting a market of 3.5 million individuals. SLN360 is on track for topline data in Q1 2022, while the company aims to deliver 2-3 INDs annually from 2023. The FDA has accepted SLN124's IND for myelodysplastic syndrome (MDS), and ongoing studies in thalassemia are expected to yield topline results in Q3 2022.

Silence Therapeutics has announced plans to cancel the admission of its ordinary shares to trading on AIM and transition the primary trading venue to Nasdaq. This AIM Delisting is set to take effect on 30 November 2021, with the last trading day on AIM being 29 November 2021. The company aims to enhance liquidity for its American Depositary Shares (ADSs) and streamline operations. A general meeting is scheduled for 1 November 2021 to seek shareholder approval. This significant change is expected to attract more US-based investors and reduce compliance costs.

Silence Therapeutics (AIM:SLN, Nasdaq: SLN) and Hansoh Pharma (3692.HK) have announced a collaboration to develop therapeutics using Silence’s mRNAi GOLD™ platform. Hansoh will make an upfront cash payment of $16 million, with Silence eligible for up to $1.3 billion in milestone payments. The partnership enables exclusive rights to two targets for Silence in regions excluding China, while Hansoh retains rights in China and global rights to a third target. Silence anticipates that this collaboration will advance its proprietary programs and provide access to the significant Chinese pharmaceutical market.

Silence Therapeutics plc (AIM: SLN, Nasdaq: SLN) will host its R&D Day on October 21, 2021, in New York City, featuring presentations on its mRNAi GOLD™ platform programs. This includes insights into lead clinical programs SLN360, targeting cardiovascular disease from high lipoprotein(a), and SLN124, aimed at treating thalassemia and myelodysplastic syndrome. The event will run from 9:00 a.m. to 11:30 a.m. EDT and will be available via a live webcast. Attendees must pre-register and provide proof of COVID-19 vaccination to enter.

Silence Therapeutics (AIM: SLN, Nasdaq: SLN) will participate in a fireside chat during the Chardan Virtual Genetic Medicines Conference on October 5 at 8:30 a.m. EDT. The event highlights the company's innovative siRNA therapeutics aimed at addressing diseases with significant unmet medical needs. A live webcast will be available on their website, and an archived replay will follow. Silence's ongoing projects include SLN360 for cardiovascular risk and SLN124 for iron-loading anemia.

Silence Therapeutics has appointed Dr. John Strafford as Senior Vice President of Business Development, Alliance Management, and New Product Development, effective immediately. Dr. Strafford, who has been with the company since 2018 and previously served as Vice President, will continue to advance business development efforts and lead the new product development function. His past collaborations with major firms like AstraZeneca have generated over $100 million in upfront payments, with total potential deal values exceeding $6 billion.

Silence Therapeutics (AIM: SLN, Nasdaq: SLN) will participate in two virtual investor conferences in September 2021. The events include the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, featuring a fireside chat at 11:45am EDT, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, available on-demand starting at 7:00am EDT. Interested parties can access the webcasts through the Investors section of Silence's website, where archived replays will also be available.

Silence Therapeutics reported strong execution in its half-year results for 2021, achieving full enrollment for four cohorts of the APOLLO study on SLN360, which targets high lipoprotein(a) levels. The company raised £30.8 million from a successful private placement and increased its cash position to £81.2 million. Positive clinical data from the SLN124 study also supports ongoing programs. However, R&D and administrative expenses rose significantly compared to 2020, reflecting investment in personnel and clinical trials. Upcoming data from the APOLLO study is anticipated in Q1 2022.